Enanta Pharma (ENTA) Announces New Data from VIEKIRAX + EXVIERA Phase 3 in Genotype 1b HCV
Tweet Send to a Friend
Enanta Pharmaceuticals, Inc., (Nasdaq: ENTA) announced new data showing high response rates with just eight weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE